Impel Pharmaceuticals (NASDAQ:IMPL) Stock Price Up 2.1%

Shares of Impel Pharmaceuticals Inc. (NASDAQ:IMPLGet Rating) rose 2.1% during trading on Monday . The company traded as high as $6.94 and last traded at $6.75. Approximately 25,263 shares traded hands during trading, a decline of 71% from the average daily volume of 85,952 shares. The stock had previously closed at $6.61.

Wall Street Analyst Weigh In

Separately, Jonestrading initiated coverage on shares of Impel Pharmaceuticals in a research note on Wednesday, August 24th. They set a “buy” rating and a $26.00 price target for the company.

Impel Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 12.07, a quick ratio of 5.88 and a current ratio of 6.25. The stock has a market cap of $160.24 million, a P/E ratio of -1.48 and a beta of -0.38. The company’s 50 day moving average price is $7.85 and its 200-day moving average price is $7.53.

Impel Pharmaceuticals (NASDAQ:IMPLGet Rating) last posted its earnings results on Monday, August 15th. The company reported ($1.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.04. Impel Pharmaceuticals had a negative net margin of 1,949.08% and a negative return on equity of 255.18%. The firm had revenue of $2.80 million during the quarter, compared to analyst estimates of $2.72 million. Equities analysts forecast that Impel Pharmaceuticals Inc. will post -4.02 EPS for the current fiscal year.

Institutional Trading of Impel Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Impel Pharmaceuticals by 8.1% in the 1st quarter. Vanguard Group Inc. now owns 531,784 shares of the company’s stock worth $3,387,000 after acquiring an additional 40,032 shares in the last quarter. DCF Advisers LLC boosted its holdings in shares of Impel Pharmaceuticals by 19.5% in the 2nd quarter. DCF Advisers LLC now owns 438,566 shares of the company’s stock worth $4,087,000 after buying an additional 71,508 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Impel Pharmaceuticals in the 4th quarter worth about $1,802,000. State Street Corp boosted its holdings in shares of Impel Pharmaceuticals by 6.6% in the 1st quarter. State Street Corp now owns 180,045 shares of the company’s stock worth $1,147,000 after buying an additional 11,107 shares during the last quarter. Finally, Opaleye Management Inc. purchased a new position in shares of Impel Pharmaceuticals in the 2nd quarter worth about $1,348,000. Institutional investors own 63.57% of the company’s stock.

About Impel Pharmaceuticals

(Get Rating)

Impel NeuroPharma, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine.

Read More

Receive News & Ratings for Impel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.